EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Biology and therapeutic targeting of molecular mechanisms in MPNs

Joan How, Jacqueline S Garcia iD, Ann Mullally iD

Blood · 2023

DOI: 10.1182/blood.2022017416 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, 2023. Verfasst von Joan How und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by activated Janus kinase (JAK)–signal transducer and activator of transcription signaling. As a result, JAK inhibitors have been the standard therapy for treatment of patients with myelofibrosis (MF). Although currently approved JAK inhibitors successfully ameliorate MPN-related symptoms, they are not known to substantially alter the MF disease course. Similarly, in essential thrombocythemia and polycythemia vera, treatments are primarily aimed at reducing the risk of cardiovascular and thromboembolic complications, with a watchful waiting approach often used in patients who are considered to be at a lower risk for thrombosis. However, better understanding of MPN biology has led to the development of rationally designed therapies, with the goal of not only addressing disease complications but also potentially modifying disease course. We review the most recent data elucidating mechanisms of disease pathogenesis and highlight emerging therapies that target MPN on several biologic levels, including JAK2-mutant MPN stem cells, JAK and non-JAK signaling pathways, mutant calreticulin, and the inflammatory bone marrow microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsMyeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisHumansJanus Kinase 2Janus KinasesDisease ProgressionBiologyMutationTumor Microenvironment

Substanzen

Janus Kinase InhibitorsJanus Kinase 2Janus Kinases

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Cancer Program, Broad Institute, Cambridge, MA.

ORCID-Profile: Jacqueline S Garcia, Ann Mullally

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

How, J., Garcia, J. S., & Mullally, A. (2023). Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. https://doi.org/10.1182/blood.2022017416

Vancouver

How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. 2023. doi:10.1182/blood.2022017416

BibTeX
@article{How2023,
  author = {How, Joan and Garcia, Jacqueline S and Mullally, Ann},
  title = {Biology and therapeutic targeting of molecular mechanisms in MPNs},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017416}
}
Kostenlos starten →